| 臺大學術典藏 |
2022-04-21T06:51:02Z |
Changes in peripheral blood lymphocyte phenotypes distribution in patients with oral cancer/oral leukoplakia in Taiwan
|
Lee J.J.; Lin C.L.; Chen, Tony Hsiu Hsi; Kok S.H.; Chang M.C.; Jeng J.H. |
| 臺大學術典藏 |
2022-04-20T08:12:04Z |
Accuracy of long-form data in the Taiwan cancer registry
|
Kao C.-W.; CHUN-JU CHIANG; Lin L.-J.; Huang C.-W.; Lee W.-C.; Lee M.-Y.; Cheng-Yi S.; Lin H.-L.; Lin M.-M.; Wang Y.-P.; Chen M.-L.; Lin K.-C.; Shen Y.-Y.; Wu S.-C.; Cheng S.-C.; Chen P.-L.; Lin Y.-C.; Wang S.-L.; Cheng C.-Y.; Chen C.-M.; Chen S.-C.; Cheng H.-W.; Chiang L.-Y.; Kao W.-L.; Su-Chien L.; Chang C.-F.; Chen T.-C.; Liau W.-L.; Lin C.-L.; Lee C.-L.; Suen Y.-Y.; Wang C.-H.; Lai W.-J.; Huang T.-Y.; Lin Y.-R.; Kao H.-Y.; Wei L.-H.; Huang C.-C.; Kuo M.-L.; Huang C.-P.; Chen S.-W.; Chiu L.-F.; Chang H.-T.; Lin L.-C.; the Taiwan Society of Cancer Registry Expert Group, Senior Cancer Registrars |
| 臺大學術典藏 |
2022-04-20T07:19:32Z |
Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area
|
Shih W.-L.; Yu M.-W.; Chen P.-J.; Yeh S.-H.; Lo M.-T.; Chang H.-C.; Liaw Y.-F.; Lin S.-M.; Liu C.-J.; Lee S.-D.; Lin C.-L.; CHUHSING KATE HSIAO; Yang S.-Y.; Chen C.-J. |
| 臺大學術典藏 |
2022-03-31T02:38:47Z |
Danshen improves survival of patients with advanced lung cancer and targeting the relationship between macrophages and lung cancer cells
|
Wu C.-Y.; Cherng J.-Y.; Yang Y.-H.; Lin C.-L.; Kuan F.-C.; Lin Y.-Y.; Lin Y.-S.; Shu L.-H.; Cheng Y.-C.; Liu H.T.; Lu M.-C.; Lung J.; PAU-CHUNG CHEN; Lin H.K.; Lee K.-D.; Tsai Y.-H. |
| 臺大學術典藏 |
2022-03-31T02:38:46Z |
Diabetes and risk of Kaposi's sarcoma: Effects of high glucose on reactivation and infection of Kaposi's sarcoma-associated herpesvirus
|
Chang P.-J.; Yang Y.-H.; PAU-CHUNG CHEN; Chen L.-W.; Wang S.-S.; Shih Y.-J.; Chen L.-Y.; Chen C.-J.; Hung C.-H.; Lin C.-L. |
| 臺大學術典藏 |
2022-03-29T06:59:57Z |
Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma
|
Huang B.-Y.; Tsai M.-R.; Hsu J.-K.; CHING-YU LIN; Lin C.-L.; Hu J.-T.; Huang Y.-W.; Liu C.-J.; Wu W.-J.; Wu C.-F.; Sung F.-Y.; Chen P.-J.; Liang H.-J.; Lin S.-M.; Yu M.-W. |
| 臺大學術典藏 |
2022-03-07T07:05:53Z |
Renin-angiotensin system genes polymorphisms and long-term prognosis in taiwanese patients with hypertension and coronary artery disease
|
Wu C.-K.; JEN-KUANG LEE; Lin L.-Y.; Huang Y.-T.; Hwang J.J.; Lin C.-L.; Tseng C.-D.; Chiang F.-T. |
| 臺大學術典藏 |
2022-03-07T07:05:52Z |
Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: A 12-year follow-up study
|
JEN-KUANG LEE; Wu C.-K.; Tsai C.-T.; Lin L.-Y.; Lin J.-W.; Chien K.-L.; Hwang J.-J.; Lin C.-L.; Tseng C.-D.; Chiang F.-T. |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-23T02:12:21Z |
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; CHIEN-HUNG CHEN; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; Liu C.-J.; Dai C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.; Yu M.-L.; TACR investigators |
| 臺大學術典藏 |
2022-02-23T02:12:20Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; CHIEN-HUNG CHEN; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; Liu C.-J.; Dai C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.; Yu M.-L.; TACR investigators |
| 臺大學術典藏 |
2022-02-18T08:25:58Z |
Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice
|
Wu W.-K.; CHIEH-CHANG CHEN; Liu P.-Y.; Panyod S.; Liao B.-Y.; Chen P.-C.; Kao H.-L.; Kuo H.-C.; Kuo C.-H.; Chiu T.H.T.; Chen R.-A.; Chuang H.-L.; Huang Y.-T.; Zou H.-B.; Hsu C.-C.; Chang T.-Y.; Lin C.-L.; Ho C.-T.; Yu H.-T.; Sheen L.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-14T06:28:46Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; YU-JEN FANG; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-27T07:34:26Z |
Vertebral compression fracture related to pancreatic cancer with osteoblastic metastasis a case report and literature review
|
Chih Y.-P.; WEI-TING WU; Lin C.-L.; Jou H.-J.; Huang Y.-H.; Chen L.-C.; Chou L.-W. |
| 臺大學術典藏 |
2022-01-27T07:34:26Z |
Application of Kinesio Taping method for newborn swallowing difficultly: A case report and literature review
|
Lin C.-L.; WEI-TING WU; Chang K.-V.; Lin H.-Y.; Chou L.-W. |
| 臺大學術典藏 |
2022-01-25T05:10:44Z |
Interferon �\-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
Liu C.-J.; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; CHI-LING CHEN; Chen P.-J.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-25T05:07:22Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; CHI-LING CHEN; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2022-01-25T03:25:12Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; CHI-LING CHEN; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2022-01-24T09:32:29Z |
Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B
|
Lin C.-L.; Liao L.-Y.; CHUN-JEN LIU; Chen P.-J.; Lai M.-Y.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:32:29Z |
Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan
|
Yu M.-W.; Chang H.-C.; Chen P.-J.; CHUN-JEN LIU; Liaw Y.-F.; Lin S.-M.; Lee S.-D.; Lin S.-C.; Lin C.-L.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:28Z |
Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women
|
Yu M.-W.; Yang Y.-C.; Yang S.-Y.; Chang H.-C.; Liaw Y.-F.; Lin S.-M.; CHUN-JEN LIU; Lee S.-D.; Lin C.-L.; Chen P.-J.; Lin S.-C.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:27Z |
Role of Reproductive Factors in Hepatocellular Carcinoma: Impact on Hepatitis B- and C-Related Risk
|
Yu M.-W.; Chang H.-C.; Chang S.-C.; Liaw Y.-F.; Lin S.-M.; CHUN-JEN LIU; Lee S.-D.; Lin C.-L.; Chen P.-J.; Lin S.-C.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:26Z |
Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma
|
Yu M.-W.; Yang S.-Y.; Pan I.-J.; Lin C.-L.; CHUN-JEN LIU; Liaw Y.-F.; Lin S.-M.; Chen P.-J.; Lee S.-D.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:21Z |
Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma
|
Chen C.-C.; Yang S.-Y.; CHUN-JEN LIU; Lin C.-L.; Liaw Y.-F.; Lin S.-M.; Lee S.-D.; Chen P.-J.; Chen C.-J.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:32:20Z |
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men
|
Yu M.-W.; Yeh S.-H.; Chen P.-J.; Liaw Y.-F.; Lin C.-L.; CHUN-JEN LIU; Shih W.-L.; Kao J.-H.; Chen D.-S.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:16Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
CHUN-JEN LIU; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; Chen C.-L.; Chen P.-J.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:32:15Z |
Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area
|
Shih W.-L.; Yu M.-W.; Chen P.-J.; Yeh S.-H.; Lo M.-T.; Chang H.-C.; Liaw Y.-F.; Lin S.-M.; CHUN-JEN LIU; Lee S.-D.; Lin C.-L.; Hsiao C.K.; Yang S.-Y.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:14Z |
Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma
|
Lin C.-L.; Chen J.-D.; CHUN-JEN LIU; Lee P.-H.; Chen P.-J.; Lai M.-Y.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:32:12Z |
Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels
|
Lin C.-L.; Liao L.-Y.; CHUN-JEN LIU; Yu M.-W.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:32:12Z |
Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan
|
Tseng T.-C.; CHUN-JEN LIU; Chen P.-J.; Lai M.-Y.; Lin C.-L.; Kao J.-K.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:32:10Z |
Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma
|
Chou Y.-C.; Yu M.-W.; Wu C.-F.; Yang S.-Y.; Lin C.-L.; CHUN-JEN LIU; Shin W.-L.; Chen P.-J.; Liaw Y.-F.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:10Z |
Reply [2]
|
Lin C.-L.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:32:10Z |
Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men
|
Wu C.-F.; Yu M.-W.; Lin C.-L.; CHUN-JEN LIU; Shih W.-L.; Tsai K.-S.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:06Z |
Body-mass index and progression of hepatitis B: A population-based cohort study in men
|
Yu M.-W.; Shih W.-L.; Lin C.-L.; CHUN-JEN LIU; Jian J.-W.; Tsai K.-S.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:02Z |
Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study
|
Shih W.-L.; Yu M.-W.; Chen P.-J.; Wu T.-W.; Lin C.-L.; CHUN-JEN LIU; Lin S.-M.; Tai D.-I.; Lee S.-D.; Liaw Y.-F. |
| 臺大學術典藏 |
2022-01-24T09:31:57Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng T.-C.; Yu M.-L.; CHUN-JEN LIU; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; Liu C.-H.; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:56Z |
Hepatitis B viraemia: Its heritability and association with common genetic variation in the interferon γ signalling pathway
|
Huang H.-H.; Shih W.-L.; Li Y.-H.; Wu C.-F.; Chen P.-J.; Lin C.-L.; CHUN-JEN LIU; Liaw Y.-F.; Lin S.-M.; Lee S.-D.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:54Z |
Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: Results from 17-year follow-up of a population-based cohort
|
Chao L.-T.; Wu C.-F.; Sung F.-Y.; Lin C.-L.; CHUN-JEN LIU; Huang C.-J.; Tsai K.-S.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:52Z |
Host genetic variants and hepatitis b virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission
|
Lin C.-L.; Tseng T.-C.; Su T.-H.; CHUN-JEN LIU; Chen P.-J.; Lai M.-Y.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:51Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; CHUN-JEN LIU; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:51Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; CHUN-JEN LIU; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:49Z |
Influences of tobacco and alcohol use on hepatocellular carcinoma survival
|
Shih W.-L.; Chang H.-C.; Liaw Y.-F.; Lin S.-M.; Lee S.-D.; Chen P.-J.; CHUN-JEN LIU; Lin C.-L.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:47Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:45Z |
Impact of Genetic Heterogeneity in Polymerase of Hepatitis B Virus on Dynamics of Viral Load and Hepatitis B Progression
|
Huang C.-J.; Wu C.-F.; Lan C.-Y.; Sung F.-Y.; Lin C.-L.; CHUN-JEN LIU; Liu H.-F.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:44Z |
Identification of a liver cirrhosis signature in plasma for predicting hepatocellular carcinoma risk in a population-based cohort of hepatitis B carriers
|
Liu C.-C.; Wang Y.-H.; Chuang E.Y.; Tsai M.-H.; Chuang Y.-H.; Lin C.-L.; CHUN-JEN LIU; Hsiao B.-Y.; Lin S.-M.; Liu L.-Y.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:38Z |
Circulating programmed death-1 as a marker for sustained high hepatitis b viral load and risk of hepatocellular carcinoma e95870
|
Cheng H.-Y.; Kang P.-J.; Chuang Y.-H.; Wang Y.-H.; Jan M.-C.; Wu C.-F.; Lin C.-L.; CHUN-JEN LIU; Liaw Y.-F.; Lin S.-M.; Chen P.-J.; Lee S.-D.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:37Z |
Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B
|
Lin C.-L.; Liu C.-H.; Wang C.-C.; Liang C.-C.; Su T.-H.; CHUN-JEN LIU; Kao J.-H. |
